Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2007

01-05-2007 | Original Article

Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings

Authors: Lorenzo Cohen, Carl A. de Moor, Peter Eisenberg, Eileen E. Ming, Henry Hu

Published in: Supportive Care in Cancer | Issue 5/2007

Login to get access

Abstract

Goals of work

The present study sought to determine the prevalence of acute and delayed chemotherapy-induced nausea and vomiting (CINV) across ten community oncology settings. The effect of CINV on quality of life (QOL) was also evaluated.

Materials and methods

Cancer patients who were scheduled for their first cycle of a new chemotherapy regimen were recruited from ten community oncology clinics. Study participants recorded occurrence of CINV by completing a daily diary each day for the first 8 days after treatment during each cycle and the Functional Living Index-Emesis (FLIE) before chemotherapy, at the end of day 1 and day 6 after chemotherapy. Mixed model regression analysis was used to explore the association between occurrence of CINV at cycle 1 and subsequent cycles and its impact on patient QOL.

Main results

One hundred and fifty-one patients provided information for at least one cycle. During cycle 1, only 33% had neither acute nor delayed CINV. Of the 36% patients who developed acute CINV, 8% developed acute CINV only. Of the 59% who developed delayed CINV, 53% reported delayed only and 47% reported acute and delayed CINV. A similar pattern was seen at cycles 2 and 3. Experience of CINV at cycle 1 was associated with the development of CINV at cycles 2 and 3. Occurrence of CINV significantly interfered with patient QOL as assessed by the FLIE.

Conclusions

CINV remained a substantial problem for patients receiving chemotherapy in this community-based sample, especially delayed CINV. CINV significantly interfered with patient QOL and daily functioning.
Literature
1.
Blower PR (1990) The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 26(Suppl 1):S8–S11PubMed
2.
De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:834–840PubMed
3.
Dibble SL, Isreal J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30:E40–E47PubMed
4.
Gandara DR (1991) Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 27(suppl):9–11
5.
Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ (1992) The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 19:67–71PubMed
6.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (2000) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971–2994
7.
Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195PubMed
8.
Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268PubMedCrossRef
9.
Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF (1996) A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 38:323–328PubMedCrossRef
10.
Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596–600PubMed
11.
Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109PubMed
12.
Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880–2886PubMedCrossRef
13.
International (Perugia) Consensus on Antiemetic Therapy (1988) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Support Care Cancer 6:197–261
14.
Italian Group for Antiemetic Research (1994) Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol 5:585–589
15.
Kris MG, Gralla RJ, Clark RA, Tyson LB, O’Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379–1384PubMed
16.
Kris MG, Tyson LB, Clark RA, Gralla RJ (1992) Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer 70:1012–1016PubMed
17.
Lindley CM, Bernard S, Fields SM (1989) Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142–1149PubMed
18.
Martin AR, Pearson J, Cai B, Elmer M, Horgan K, Lindley C (2000) Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res 9(3):P-18
19.
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–821PubMedCrossRef
20.
Mason BA, Dambra J, Grossman B, Catalano RB (1982) Effective control of cisplatin-induced nausea using high-dose steroids and droperidol. Cancer Treat Rep 66:243–245PubMed
21.
Moreno I, Rosell R, Abad A, Barnadas A, Carles J, Ribelles N, Solano V, Font A (1992) Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 28A:1344–1347PubMedCrossRef
22.
Morrow GR, Hickok JT, Burish TG, Rosenthal SN (1996) Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 19:199–203PubMedCrossRef
23.
No authors listed (1997) NCCN antiemesis practice guidelines. Oncology (Williston Park) 11:57–89
24.
Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116–123PubMed
25.
Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, Patoia L, Santi E, Penza O, Ballatori E et al (1991) Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 14:238–242PubMedCrossRef
26.
Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2:472–483PubMed
27.
Voliotis DL, Diehl V (1998) Clinical aspects and prognostic factors of nausea and vomiting after chemotherapy. In: DiCato MA (ed) Medical management of cancer treatment induced emesis. Martin Dunitz, Philadelphia, pp 45–54
Metadata
Title
Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings
Authors
Lorenzo Cohen
Carl A. de Moor
Peter Eisenberg
Eileen E. Ming
Henry Hu
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 5/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0173-z

Other articles of this Issue 5/2007

Supportive Care in Cancer 5/2007 Go to the issue

Original Article

Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies

Original Article

Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies

Original Article

Social support among women who died of ovarian cancer

Supportive Care International

The impact of the palliative care mobile team on symptom assessment and medication profiles in patients admitted to a comprehensive cancer center

Original Article

The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer

Forthcoming Meetings

Forthcoming Meetings
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits